winesoreo.blogg.se - Affinity designer trial

Affinity designer trial trial#

The post-hoc analysis of SYNERGY data indicated an increased clinical effect of opicinumab versus placebo (when used at the same time as interferon beta-1a intramuscular injection) in patients who had the disease for shorter periods of time and in whom MRI showed certain brain features that suggest repair of MS lesions may be possible through remyelination. These data are being presented at MSParis2017, the seventh Joint Meeting of the European Committee for Treatment and Research in MS and Americas Committee for Treatment and Research in MS (ECTRIMS-ACTRIMS 25 – 28 October).

Affinity designer trial trial#

The trial follows the comprehensive review of SYNERGY, a Phase 2 trial, which identified a specific population that may be more likely to respond to treatment.

Opicinumab – a first-in-class human monoclonal antibody directed against LINGO-1 – is being evaluated to determine its potential for improving pre-existing disability in relapsing MS patients through remyelinationĬAMBRIDGE, Mass.-( BUSINESS WIRE)- Biogen (NASDAQ: BIIB) announced today the recent initiation of the Phase 2 clinical trial AFFINITY, designed to evaluate opicinumab as an investigational add-on therapy in people with relapsing multiple sclerosis (MS).

Comprehensive review of the SYNERGY trial data identified a specific patient population that merits more study of opicinumab.

AFFINITY to evaluate opicinumab as an investigational add-on therapy in people with relapsing multiple sclerosis (MS) with trial design guided by the findings from SYNERGY.